ECG monitoring to detect atrial fibrillation after stroke

ISRCTN ISRCTN97412358
DOI https://doi.org/10.1186/ISRCTN97412358
Secondary identifying numbers N/A
Submission date
18/03/2010
Registration date
28/04/2010
Last edited
18/03/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
Atrial fibrillation is a heart condition that causes an irregular heart rate. It can cause blood clots in the heart, which can break up, escape from the heart and become lodged in the blood vessels supplying the brain, causing a stroke. Stroke patients with atrial fibrillation are therefore at a higher risk of having another stroke, but atrial fibrillation is not always identified by the standard investigations performed after a stroke. An electrocardiogram (ECG) is a simple test to check the heart's rhythm and electrical activity. The aim of this study is to find out whether additional ECG monitoring early after stroke speeds up the detection of atrial fibrillation and the start of effective treatment.

Who can participate?
Patients who have had a stroke in the last week

What does the study involve?
Participants are randomly allocated to one of two groups. One group receives standard care, and the other group receives additional ECG monitoring (two additional 12-lead ECGs plus 3 to 7 days' continuous ECG event monitoring). We assess the number of patients with detected atrial fibrillation and starting treatment for atrial fibrillation, the costs of investigation and treatment, patient acceptability, stroke recurrence, quality of life and survival in the two groups.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Western Infirmary (UK)

When is the study starting and how long is it expected to run for?
May 2010 to December 2016

Who is funding the study?
Chief Scientist Office of the Scottish Executive Health Department (UK)

Who is the main contact?
Prof. Kennedy Lees
k.r.lees@clinmed.gla.ac.uk

Contact information

Prof Kennedy R Lees
Scientific

Acute Stroke Unit & Cerebrovascular Clinic
Western Infirmary
44 Church Street
and
Cardiovascular & Medical Sciences
Faculty of Medicine
University of Glasgow
Glasgow
G11 6NT
United Kingdom

Email k.r.lees@clinmed.gla.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeDiagnostic
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEvaluation of electrocardiographic monitoring strategy to identify atrial fibrillation in patients with recent acute stroke: a randomised controlled trial
Study hypothesisIntensive investigation for atrial fibrillation amongst patients with acute stroke or confirmed transient ischaemic attack (TIA) who are admitted or initially assessed in sinus rhythm will detect 5% who have unrecognised episodes of atrial fibrillation/flutter; and 3.5% who will be suitable to commence oral anticoagulation, rendering a policy of more intensive investigation cost-effective in the NHS.
Ethics approval(s)Scotland A Research Ethics Committee, 17/08/2009, ref: 09/MRE00/59
ConditionIschaemic stroke
InterventionControl: standard care
Intervention: two additional 12-lead ECGs plus 3 - 7 days' continuous ECG event monitoring

Duration of intervention: 7 days
Duration of follow-up: 1 year direct; 5 years electronic
Intervention typeOther
Primary outcome measureAbsolute number of patients with AF or atrial flutter detected within two weeks of stroke.
Secondary outcome measuresSecondary outcomes:
1. Absolute number of patients with AF or atrial flutter detected within 90 days and one year of stroke
2. Absolute number of patients commenced on oral anticoagulation within two weeks and one year of stroke
3. Marginal cost of investigation
4. Marginal cost of treatment
5. Patient acceptability
6. Time to recognition of AF/flutter

Tertiary outcomes:
1. Stroke recurrence within one year
2. Distribution of modified Rankin scale at one year (assessed centrally by recorded interview to ensure objectivity)
3. 'Home time' over 90 days - an objective measure of early functional outcome
4. EQ-5D quality of life at one year (in patients who can complete this, or by proxy)
5. Five-year survival (by flagging with ONS)
6. Predictors of AF amongst eligible patients
7. AF duration 'threshold' for use of anticoagulation
Overall study start date01/05/2010
Overall study end date31/12/2016

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants5000
Participant inclusion criteria1. Diagnosis of acute ischaemic stroke or confirmed transient ischaemic attack, within one week of symptom onset (participants are of any age and sex)
2. Brain imaging completed prior to enrolment is consistent with acute ischaemic damage and has excluded an alternative cause for symptoms
3. Sinus rhythm on screening ECG
4. Consent to participate from patient or approved proxy
Participant exclusion criteria1. Clinical decision or expressed refusal to consider long term anticoagulation at a future date if cardio-embolism may be diagnosed
2. Pre-morbid condition or concomitant disease that would render subsequent secondary prevention of stroke inappropriate
3. Documented atrial fibrillation in past
4. Known durable cardiac source of embolism (eg mitral stenosis) or left ventricular akinesia, that would represent an indication for anticoagulation
5. Existing treatment with long term anticoagulation
6. Unlikely to be available for completion of study procedures
Recruitment start date01/05/2010
Recruitment end date31/12/2016

Locations

Countries of recruitment

  • Scotland
  • United Kingdom

Study participating centre

Western Infirmary
Glasgow
G11 6NT
United Kingdom

Sponsor information

NHS Greater Glasgow & Clyde (UK)
Government

Research and Development Central Office
Western Infirmary
1st Floor, Tennent Institute
38 Church Street
Glasgow
G11 6NT
United Kingdom

Website http://www.nhsggc.org.uk/r&d
ROR logo "ROR" https://ror.org/05kdz4d87

Funders

Funder type

Government

Chief Scientist Office
Government organisation / Local government
Alternative name(s)
CSO
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/09/2013 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

18/03/2016: Plain English summary added.